Isomorphic Labs, the DeepMind spin-off, has closed a Series B funding round of $2.1 billion. The operation, led by Thrive Capital and backed by Alphabet, GV, and new investors, aims to expand its AI platform for designing small molecules, antibodies, and RNA therapies.
AlphaFold as the foundation for AI-assisted molecular design 🧬
The company uses generative and predictive AI models to accelerate the identification of drug candidates. Its technology relies on AlphaFold, the protein structure prediction system, but now focuses on concrete applications: designing molecules that bind to therapeutic targets. The platform integrates simulations and machine learning to optimize pharmacological properties from early stages.
$2.1 billion so AI doesn't hallucinate the drug 💊
With that money, Isomorphic Labs could buy enough servers to fill a hangar and still have change for coffee. The promise is that AI will design molecules that work, not just look pretty on a screen. Let's see if this time the algorithm doesn't confuse a protein with a pizza, because with $2.1 billion, investors expect results, not molecular memes.